{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:46:31Z","timestamp":1782254791296,"version":"3.54.5"},"reference-count":39,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The advent of tyrosine kinase inhibitors (TKI) has revolutionised the treatment of chronic myeloid leukaemia (CML). Nevertheless, no specific tools are currently available to support follow-up and guarantee the adequate management of safety, adherence, and effectiveness altogether of TKI-based regimens. This study aimed to introduce a monitoring instrument tailored to patients undergoing TKI therapy for CML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Source<\/jats:title>\n                    <jats:p>A structured instrument proposal was developed after conducting an integrative review. The instrument was then evaluated by clinicians and laboratory professionals with expertise in onco-haematology, who assessed clarity, objectivity, practicality, and clinical relevance using a five-point Likert scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Summary<\/jats:title>\n                    <jats:p>The model comprised three protocols designed to evaluate adherence, safety, and effectiveness of TKI therapy. During evaluation of the instrument, all assessed parameters achieved mean scores \u2265 3.0. By aligning with international guidelines, the instrument consolidates essential monitoring parameters, thereby enhancing clinical decision-making and supporting patient-centred care in CML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Instruments of this nature are rare and represent an important challenge for healthcare teams managing CML patients. Considering that adherence and safety are critical determinants of therapeutic success, structured tools such as this have the potential to facilitate improved outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261423064","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:15:58Z","timestamp":1772453758000},"page":"946-955","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapeutic monitoring of tyrosine kinase inhibitors use in patients with chronic myeloid leukaemia: An integrative model proposal"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2409-779X","authenticated-orcid":false,"given":"Gustavo Catarina","family":"Galdino","sequence":"first","affiliation":[{"name":"Post-graduate Program in Pharmacy, Health Sciences Center, Universidade Federal de Santa Catarina, Florian\u00f3polis, SC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana Aparecida","family":"Rodrigues Pais","sequence":"additional","affiliation":[{"name":"Post-graduate Program in Pharmaceutical Services, Universidade Federal de Santa Catarina, Florian\u00f3polis, SC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vict\u00f3ria Mattozo","family":"Rover","sequence":"additional","affiliation":[{"name":"Universidade Federal de Santa Catarina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Raijche","family":"Mattozo Rover","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Department, Health Sciences Center, Universidade Federal de Santa Catarina, Florian\u00f3polis, SC, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-71913-5_3"},{"key":"e_1_3_3_3_2","unstructured":"Surveillance Epidemiology and End Results Program (US). National Cancer Institute. Cancer stat facts: chronic myeloid leukemia (CML) [Internet]. 2023."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.139337"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000468"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103580"},{"key":"e_1_3_3_7_2","first-page":"22","article-title":"From gloom to glee with imatinib: the story of the drug that conquered chronic myeloid leukemia","volume":"1","author":"Paralikar S","year":"2023","unstructured":"Paralikar S. From gloom to glee with imatinib: the story of the drug that conquered chronic myeloid leukemia. Natl J Pharmacol Ther 2023; 1: 22\u201325.","journal-title":"Natl J Pharmacol Ther"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S269355"},{"key":"e_1_3_3_9_2","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: chronic myeloid leukemia [Internet]. 2022 [cited 2023 Jul 2]. Available from: https:\/\/www.nccn.org\/patients."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03446-1"},{"key":"e_1_3_3_11_2","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Protocolo cl\u00ednico e diretrizes terap\u00eauticas: leucemia mieloide cr\u00f4nica no adulto. Portaria Conjunta n\u00b0 4 de 1\u00b0 de mar\u00e7o de 2021."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12723"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219864640"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-64263-5_5"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0258-1"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.206797"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx219"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/hex.12515"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/scs.12531"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101450"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000818"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1399"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S32822"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2017.01.004"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01470-z"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.2852"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-011711-113247"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/2327-6924.12099"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00400.x"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23180"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108256"},{"key":"e_1_3_3_34_2","first-page":"362","article-title":"In vitro assessment of the role of CYP3A4 and CYP2C8 in the metabolism of imatinib and interactions with antifungal azoles","volume":"114","author":"Filppula AM","year":"2014","unstructured":"Filppula AM, Neuvonen PJ, Backman JT. In vitro assessment of the role of CYP3A4 and CYP2C8 in the metabolism of imatinib and interactions with antifungal azoles. Basic Clin Pharmacol Toxicol 2014; 114: 362\u2013370.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70579-5"},{"key":"e_1_3_3_36_2","first-page":"663","article-title":"Drug - drug interactions with imatinib: clinical and pharmacokinetic considerations","volume":"105","author":"Novartis","year":"2005","unstructured":"Novartis. Drug - drug interactions with imatinib: clinical and pharmacokinetic considerations. Blood 2005; 105: 663\u2013670.","journal-title":"Blood"},{"key":"e_1_3_3_37_2","first-page":"574170","article-title":"Pharmacokinetic interactions between tyrosine kinase inhibitors and antiepileptics: focus on CYP3A4 induction","volume":"11","author":"Wang Y","year":"2020","unstructured":"Wang Y, Zhou Q, Zhu W, et al. Pharmacokinetic interactions between tyrosine kinase inhibitors and antiepileptics: focus on CYP3A4 induction. Front Pharmacol 2020; 11: 574170.","journal-title":"Front Pharmacol"},{"key":"e_1_3_3_38_2","article-title":"Alectinib - warfarin interaction necessitating warfarin dose increase in a patient with ALK-positive non-small cell lung cancer","volume":"11","author":"Sato Y","year":"2023","unstructured":"Sato Y, Masuda S, Otsubo K, et al. Alectinib - warfarin interaction necessitating warfarin dose increase in a patient with ALK-positive non-small cell lung cancer. Clin Case Rep 2023; 11: e7140.","journal-title":"Clin Case Rep"},{"key":"e_1_3_3_39_2","first-page":"3821","article-title":"Drug - drug interactions between oral anticancer drugs and concomitant medications","volume":"49","author":"van Leeuwen RWF","year":"2013","unstructured":"van Leeuwen RWF, Jansman FGA, van den Bemt PMLA, et al. Drug - drug interactions between oral anticancer drugs and concomitant medications. Eur J Cancer 2013; 49: 3821\u20133832.","journal-title":"Eur J Cancer"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.139"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261423064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261423064","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261423064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:50:51Z","timestamp":1782251451000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261423064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/10781552261423064"],"URL":"https:\/\/doi.org\/10.1177\/10781552261423064","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}